.png){kind=icon}
J
Jamie E. Chaft
H指数:67
被引数:3.1万
浏览量:0
个人简介
暂无内容
教育背景
暂无内容
工作经历
暂无内容
荣誉奖项
暂无内容
SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy
SUNRAY-02：奥莫罗西比与免疫疗法联合治疗经根治性治疗后处于II-III期KRAS G12C突变型非小细胞肺癌的研究
Future Oncology
IF2.6
Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial
不可切除的III期非小细胞肺癌中，Canakinumab联合化放疗和Durvalumab巩固治疗：CHORUS I/II期试验
Nature Communications
IF15.7
Early-stage non-small-cell lung cancer: emerging treatments and evolving challenges
早期非小细胞肺癌：新兴治疗方法与演变中的挑战
PP01.48: Therapeutic Strategies and Immunotherapy Rechallenge Sensitivity After Progression Following Chemoradiation and Consolidation Durvalumab in Unresectable Stage III NSCLC: The POST-PACIFIC Study
PP01.48: 化疗放疗联合Durvalumab巩固治疗后不可切除III期NSCLC进展后的治疗策略与免疫疗法再挑战敏感性：POST-PACIFIC研究
Treatments for Human epidermal growth factor receptor 2 (HER2)–Altered cancers evaluated using a tumor‑agnostic approach: A narrative review
针对人类表皮生长因子受体2（HER2）变异癌症的治疗方法：基于肿瘤非特异方法的叙述性综述
Cancer Treatment Reviews
IF10.5
Safety profile of KRAS G12C inhibitors combined with thoracic radiation therapy
KRAS G12C抑制剂的联合胸部放射治疗安全性特征
Phase 2 study of amivantamab plus lazertinib in previously-treated patients with EGFR mutant lung cancers with brain and leptomeningeal metastases
II期研究：评估amivantamab联合lazertinib在既往经治的EGFR突变型肺癌伴脑和软脑膜转移患者中的疗效
Outcomes with neoadjuvant osimertinib and/or chemotherapy in patients with EGFR-mutant resectable non-small cell lung cancers
EGFR突变可切除非小细胞肺癌患者接受新辅助奥希替尼和/或化疗的疗效
Lung Cancer
IF4.4
Prospective validation of a pretreatment 18F-FDG PET/CT and mean lung dose model for early radiation pneumonitis
前瞻性验证一种治疗前18F-FDG PET/CT和平均肺剂量模型用于早期放射性肺炎
Brief Report: Critical Role for DNA-Based Sequencing in Discriminating Distinct Primary Lung Cancers with Different MET Exon 14 Skipping Mutations.
简报：DNA测序在区分具有不同MET外显子14跳跃突变的不同原发性肺癌中的关键作用。
Real-world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event-free survival
非小细胞肺癌患者新辅助化免疫治疗的实际结果：手术、病理完全缓解和事件无进展生存的预测因素
Cancer
IF5.1
Robotic-assisted bronchoscopy for histopathologic subtyping of primary lung adenocarcinoma
机器人辅助支气管镜检查用于原发性肺腺癌的病理亚型分类
Lung Cancer
IF4.4
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
在早期非小细胞肺癌患者中，新辅助派姆单抗加化疗后辅助派姆单抗与单独新辅助化疗的比较 (KEYNOTE-671): 一项随机，双盲，安慰剂对照的3期试验
LANCET
IF88.5
Neoadjuvant nivolumab and nivolumab plus ipilimumab in resectable non-small cell lung cancer: Combined analysis of 5-year outcomes from NEOSTAR and CA209-159
新辅助纳武利尤单抗及纳武利尤单抗联合伊匹木单抗在可切除非小细胞肺癌中的应用：NEOSTAR和CA209-159研究的5年结果联合分析
ANNALS OF ONCOLOGY
IF65.4
